Article Cited by others


Fingolimod (FTY720): First approved oral therapy for multiple sclerosis

Sharma Sushil, Mathur A G, Pradhan Sapna, Singh D B, Gupta Sparsh

Year : 2011| Volume: 2| Issue : 1 | Page no: 49-51

   This article has been cited by
1 Validating a selective S1P1 receptor modulator Syl930 for psoriasis treatment
Ming Ji,Nina Xue,Fangfang Lai,Xiaoying Zhang,Sen Zhang,Yuchen Wang,Jing Jin,Xiaoguang Chen
Biological and Pharmaceutical Bulletin. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 SPHK1-S1PR1-RANKL Axis Regulates the Interactions Between Macrophages and BMSCs in Inflammatory Bone Loss
Lan Xiao,Yinghong Zhou,Lingxin Zhu,Shasha Yang,Rong Huang,Wei Shi,Bin Peng,Yin Xiao
Journal of Bone and Mineral Research. 2018;
[Pubmed]  [Google Scholar] [DOI]
3 Fingolimod (FTY720) attenuates social deficits, learning and memory impairments, neuronal loss and neuroinflammation in the rat model of autism
Hongmei Wu,Xuelai Wang,Jingquan Gao,Shuang Liang,Yanqiu Hao,Caihong Sun,Wei Xia,Yonggang Cao,Lijie Wu
Life Sciences. 2017;
[Pubmed]  [Google Scholar] [DOI]
4 Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside
Daniele Focosi
International Reviews of Immunology. 2016; : 00
[Pubmed]  [Google Scholar] [DOI]
5 Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy
Julius O. Enoru,Barbara Yang,Sesha Krishnamachari,Ernesto Villanueva,William DeMaio,Adiba Watanyar,Ramesh Chinnasamy,Jeffrey B. Arterburn,Ruth G. Perez,Jonghan Kim
PLOS ONE. 2016; 11(9): e0162162
[Pubmed]  [Google Scholar] [DOI]
6 Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis
Robert J. Fox,Andrew Chan,Annie Zhang,James Xiao,Dane Levison,James B. Lewin,Michael R. Edwards,Jing L. Marantz
Current Medical Research and Opinion. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
7 T Cell Trafficking through Lymphatic Vessels
Morgan C. Hunter,Alvaro Teijeira,Cornelia Halin
Frontiers in Immunology. 2016; 7
[Pubmed]  [Google Scholar] [DOI]
8 Importance of Sphingosine Kinase (SphK) as a Target in Developing Cancer Therapeutics and Recent Developments in the Synthesis of Novel SphK Inhibitors
Daniel Plano,Shantu Amin,Arun K. Sharma
Journal of Medicinal Chemistry. 2014; 57(13): 5509
[Pubmed]  [Google Scholar] [DOI]
9 Review: Novel insights into the regulation of vascular tone bysphingosine 1-phosphate
D. Kerage,D.N. Brindley,D.G. Hemmings
Placenta. 2014; 35: S86
[Pubmed]  [Google Scholar] [DOI]
10 Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation.
Huang C, Das A, Barker D, Tholpady S, Wang T, Cui Q, Ogle R, Botchwey E.
Cell Tissue Res. 2012 Mar;347(3):553-66. Epub 2011 Aug 24.. 2012; 347(3): 553-566
[Pubmed]  [Google Scholar] [DOI]
11 Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation
Cynthia Huang,Anusuya Das,Daniel Barker,Sunil Tholpady,Tiffany Wang,Quanjun Cui,Roy Ogle,Edward Botchwey
Cell and Tissue Research. 2012; 347(3): 553
[Pubmed]  [Google Scholar] [DOI]
12 Immunological Function of Sphingosine 1-Phosphate in the Intestine
Kunisawa J, Kiyono H
Nutrients. 2012; 4(3): 154-166
[Pubmed]  [Google Scholar] [DOI]
13 Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis
Singh M, Cugati G, Singh P, Singh AK.
J Pharm Bioallied Sci. 2011; 3(3): 460-461
[Pubmed]  [Google Scholar] [DOI]
14 Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
Pinki, Thawani V
J Pharmacol Pharmacother. 2011; 2(3): 207
[Pubmed]  [Google Scholar] [DOI]
15 FTY720 mediates activation suppression and G0/G1 cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model
Zeng X, Wang T, Zhu C, Ye Y, Song B, Lai X, Zeng Y
Inflammation Research. ;
[Pubmed]  [Google Scholar] [DOI]


Read this article